Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company''s product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
最新股票文章

為何麥可·貝瑞(Michael Burry)剛剛清倉所有股票
麥可·貝瑞剛剛拋售了超過7,000萬美元的股票,清空了他的整個投資組合,只保留一支股票,並對這家公司加碼,而其他投資人則紛紛出逃。
18:37, 22 7月 2025

道瓊交易觀察:財報季成為市場焦點
上週,美國主要股指表現分化,其中道瓊工業指數表現相對落後於科技權重較高的指數,但從技術面來看,道瓊仍維持多頭趨勢,並持續受到CoT(持倉報告)投機者的淨多頭偏好所支撐。
17:26, 21 7月 2025